Bauke Anninga was a principal at M Ventures for two years.
Bauke Anninga has announced his promotion at M Ventures, the corporate venture capital firm of Germany-based science and technology company Merck Group.
After serving two years as the principal of M Ventures, Anninga will now act as the firm’s investment director.
He began at M Ventures in 2019 as an associate, a position he held for two years. During this time he was board director and board observer at several startups such as Rewind Therapeutics and Immunitas Therapeutics.
Before joining M Ventures, Anninga spent a year as a healthcare investment banker at Jefferies, a global investment banking company, and was the director of new ventures for a year at Cambridge Squared, a boutique life science investment company.
Founded in 2009, M Ventures invests in healthcare, IT and life sciences startups. The unit has 68 companies in its portfolio and has invested in 159 startups including Neologic, Astraveus and Nouscom.
